VAERS reports by lot

GSK DTaP/Tdap lot E2L54: VAERS reports

53 VAERS reports list lot E2L54 as a GSK DTaP/Tdap vaccine, received between 2021-10-04 and 2023-05-03. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
53
Reports
0%
Marked serious
0
With a death outcome
15
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Injection-site / Local reaction1556%
Allergic / Anaphylactic415%
Dermatological (non-injection-site)311%
Psychiatric / Neuropsychiatric27%
Neurological14%
Musculoskeletal14%
General / Systemic (non-local)14%

Where reports came from

U.S. state of the reporter, where given (top 12).

California9
Wisconsin4
Michigan3
Oklahoma3
Texas2
Colorado2
Alaska2
Pennsylvania2
Georgia2
Nebraska2
West Virginia2
Ohio2

Reports by month received

2021-102
2021-116
2021-122
2022-016
2022-022
2022-035
2022-043
2022-057
2022-071
2022-085
2022-092
2022-101
2023-015
2023-035
2023-051

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.